SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; Hereinafter “SBI Pharma”), a subsidiary of SBI Holdings, Inc., engaged in the research and development of pharmaceuticals and medical devices regarding 5-aminolevulinic acid (5‑ALA) (*1), announces that “ALAGLIO^® Divided Powder 1.5g” (Seller: Nippon Kayaku Co., Ltd.; hereinafter “the drug”) is launched today.

To ensure a stable supply of pharmaceuticals, SBI Pharma has developed a unique manufacturing method and obtained the marketing authorization for the drug in March 2026. SBI Pharma will be providing healthcare professionals with a smaller product compared to our currently available “ALAGLIO^® Oral 1.5g.”

■ Product Images

■ Product information

SBI Pharma remains committed to advancing research and development to support healthier and more fulfilling lives. SBI Pharma continues to strive to make the drug a valuable tool for both patients and healthcare professionals involved in the treatment of bladder cancer.

*1   5-ALA is an amino acid produced in the mitochondria of the body. When taken up by cancer cells, its major metabolite, protoporphyrin IX, accumulates. Upon exposure to excitation light, protoporphyrin IX emits fluorescence from the cancer cells. This protoporphyrin IX exhibits fluorescence when irradiated with excitation light, and by utilizing this property, cancer can be visualized, making it a practical intraoperative diagnostic agent for cancer, and further development is underway.

********************************************************************************
For further information:
SBI Pharmaceuticals Co., Ltd.
E-mail: info_ala@sbigroup.co.jp

Please download PDF version for printing.